<DOC>
<DOCNO>EP-0635497</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Benzospiroalkene derivatives, process for their preparation and pharmaceutical compostions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31425	C07D49500	C07D491107	A61K314162	C07D49510	C07D49800	C07D49810	A61P4300	A61K31429	A61P2500	A61K31415	A61K31415	A61K314162	C07D49100	A61K31424	A61P2506	C07D23500	A61K31423	A61P4300	A61K314184	C07D51300	A61K31425	A61K3142	C07D26352	C07D23502	A61K314188	C07D51310	A61K31423	A61P2504	A61K314164	C07D49110	A61K31429	C07D26300	A61P2502	A61K31424	A61K3142	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	C07D	A61K	C07D	C07D	C07D	A61P	A61K	A61P	A61K	A61K	A61K	C07D	A61K	A61P	C07D	A61K	A61P	A61K	C07D	A61K	A61K	C07D	C07D	A61K	C07D	A61K	A61P	A61K	C07D	A61K	C07D	A61P	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D495	C07D491	A61K31	C07D495	C07D498	C07D498	A61P43	A61K31	A61P25	A61K31	A61K31	A61K31	C07D491	A61K31	A61P25	C07D235	A61K31	A61P43	A61K31	C07D513	A61K31	A61K31	C07D263	C07D235	A61K31	C07D513	A61K31	A61P25	A61K31	C07D491	A61K31	C07D263	A61P25	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I): 
<
IMAGE
>
  in which:   - X represents -CH2-, -(CH2)2-, -CH=CH-, -O-CH2-, S-CH2-, -SO-CH2- or -SO2-CH2-,   - Y represents an oxygen or sulphur atom or a group -NR6-, - R1 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, - R2 represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group (substituted or unsubstituted), a hydroxyl group, a linear or branched (C1-C6)alkoxy group or a linear or branched (C1-C6)alkylthio group, - R3 represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group (substituted or unsubstituted), a hydroxyl group, a linear or branched (C1-C6)alkoxy group or a linear or branched (C1-C6)alkylthio group, - R4 represents a hydrogen atom (provided that, in this case, R1 represents a hydrogen atom), a halogen atom, a linear or branched (C1-C6)alkyl group (substituted or unsubstituted) or a hydroxyl group, or else - R1 and R2, R2 and R3, R3 and R4 or R4 and X form, together with the carbon atoms which carry them, a benzene ring, provided that, in the case where R1 and R2 form a benzene ring, X is other than -CH2- or -(CH2)2-, - R5 represents a hydrogen atom or an amino group (substituted or unsubstituted),   - R6 has the same meaning as R1, their isomers and their addition salts with a pharmaceutically acceptable acid. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I):


wherein:

X represents -CH
2
-, -(CH
2
)
2
-, -CH=CH-, -O-CH
2
-, -S-CH
2
-, -SO-CH
2
 or SO
2
-CH
2
-,
Y represents an oxygen or sulphur atom or a group -NR
6
-,
R
1
 represents a hydrogen atom or a linear or branched (C
1
-C
6
)alkyl group,
R
2
 represents a hydrogen or halogen atom, a linear or branched (C
1
-C
6
)alkyl group
(unsubstituted or substituted by one or more halogen atoms), a hydroxy group, a

linear or branched (C
1
-C
6
)alkoxy group or a linear or branched (C
1
-C
6
)alkylthio
group,
R
3
 represents a hydrogen or halogen atom, a linear or branched (C
1
-C
6
)alkyl group
(unsubstituted or substituted by one or more halogen atoms), a hydroxy group, a

linear or branched (C
1
-C
6
)alkoxy group or a linear or branched (C
1
-C
6
)alkylthio
group,
R
4
 represents a hydrogen atom (with the proviso that, in that case, R
1
 represents a
hydrogen atom), a halogen atom, a linear or branched (C
1
-C
6
)alkyl group
(unsubstituted or substituted by one or more halogen atoms) or a hydroxy group,

or

R
1
 and R
2
, R
2
 and R
3
, R
3
 and R
4
, or R
4
 and X, together with the carbon atoms
carrying them, form a benzene ring, with the proviso that, when R
1
 and R
2
 form a
benzene ring, X is other than -CH
2
- or -(CH
2
)
2
-,
R5 represents a hydrogen atom or an amino group (unsubstituted or substituted by
one or two linear or branched (C
1
-C
6
)alkyl groups), 
R
6
 is as defined for R
1
,

their isomers, and addition salts thereof with a pharmaceutically acceptable acid.
Compounds of formula (I) according to claim 1, wherein X represents -(CH
2
)
2
-, their
isomers, and addition salts thereof with a pharmaceutically acceptable acid.
Compounds of formula (I) according to claim 1, wherein Y represents -NH-, their
isomers, and addition salts thereof with a pharmaceutically acceptable acid.
The compounds of formula (I) according to claim 1, wherein R
1
 represents a
hydrogen atom, their isomers, and addition salts thereof with a pharmaceutically

acceptable acid.
The compounds of formula (I) according to claim 1, wherein R
5
 represents a
hydrogen atom, their isomers, and addition salts thereof with a pharmaceutically

acceptable acid.
Compound of formula (I) according to claim 1 that is spiro[(1,3-diazacyclopent-1-ene)-5
: 2'-(1',2',3',4'-tetrahydronaphthalene)]
, its isomers and addition salts thereof
with a pharmaceutically acceptable acid.
Compound of formula (I) according to claim 1 that is spiro[(1,3-diazacyclopent-1-ene)-5
: 2'-(7'-methyl-1',2',3',4'-tetrahydronaphthalene)]
, its isomers and addition salts
thereof with a pharmaceutically acceptable acid.
Process for the preparation of compounds of formula (I) according to claim 1
wherein Y represents a group -NR
6
-, characterised in that there is used as starting
material a compound of formula (II):


 
wherein X, R
1
, R
2
, R
3
 and R
4
 are as defined for formula (I),

which is reacted :

either
 with benzylamine in the presence of para-toluenesulphonic acid to yield a
compound of formula (III):



wherein X, R
1
, R
2
, R
3
 and R
4
 are as defined for formula (I),

which is reacted, under an inert atmosphere, with trimethylsilyl cyanide in the presence
of zinc iodide

to yield a compound of formula (IV):


wherein X, R
1
, R
2
, R
3
 and R
4
 are as defined for formula (I),

which is reduced with lithium aluminium hydride and then by catalytic hydrogenation to
yield a compound of formula (V):



wherein X, R
1
, R
2
, R
3
 and R
4
 are as defined for formula (I), 
or
 with potassium cyanide in the presence of ammonium chloride in an inert medium
or with sodium cyanide in an acid medium, or with trimethylsilyl cyanide in the

presence of zinc iodide and then with an alcoholic saturated ammonia solution,
to yield a compound of formula (VI):



wherein X, R
1
, R
2
, R
3
 and R
4
 are as defined for formula (I),

which is reduced with lithium aluminium hydride to yield a compound of formula (V)
described previously,

which compound of formula (V) is reacted with formamidine in an alcoholic medium, an
alkyl formate or with a cyanogen halide (followed, according to the nature of the

compound of formula (I) which it is desired to obtain, by an alkylation reaction using an
alkyl halide)

to yield a compound of formula (I/a), a particular case of the compounds of formula (I):


wherein X, R
1
, R
2
, R
3
, R
4
, R
5
 and R
6
 are as defined for formula (I),

which compound of formula (I/a)

is, if necessary, purified according to a customary purification technique,

is, if desired, separated into its isomers according to a customary purification
technique,

and is optionally converted into its addition salts with a pharmaceutically acceptable
acid.
Process for the preparation of compounds of formula (I) according to claim 1
wherein Y represents an oxygen or sulphur atom, characterised in that the compound 

of formula (VI) according to claim 8 is reacted with formic acid in an anhydrous
medium saturated with hydrochloric acid

to yield a compound of formula (VII):


wherein R
1
, R
2
, R
3
, R
4
 and X are as defined for formula (I),

which is converted in a concentrated hydrochloric medium into a corresponding acid of
formula (VIII):



wherein R
1
, R
2
, R
3
, R
4
 and X are as defined for formula (I),

which is subjected to reduction with lithium aluminium hydride in an inert medium,
to yield a compound of formula (IXa):



wherein R
1
, R
2
, R
3
, R
4
 and X are as defined for formula (I),

which compound of formula (IXa) is converted, according to the nature of the
compounds of formula (I) which it is desired to obtain, into the corresponding tosylate

using para-toluenesulphonic acid and then reacted with thiourea or thioacetic acid
to yield, after hydrolysis, a compound of formula (IXb): 



wherein R
1
, R
2
, R
3
, R
4
 and X are as defined for formula (I),

which compound of formula (IXa) or (IXb) is reacted with formamidine in an alcoholic
medium, an alkyl formate or with a cyanogen halide (followed, according to the nature

of the compound of formula (I) which it is desired to obtain, by an alkylation reaction
using an alkyl halide)

to yield a compound of formula (I/b), a particular case of the compounds of formula (I):


wherein R
1
, R
2
, R
3
, R
4
, R
5
 and X are as defined hereinbefore and Y' represents an
oxygen or sulphur atom,

which compound of formula (I/b)

is, if necessary, purified according to a customary purification technique,

is, if desired, separated into its isomers according to a customary purification
technique,

and is optionally converted into its addition salts with a pharmaceutically acceptable
acid.
Pharmaceutical compositions comprising as active ingredient at least one
compound according to any one of claims 1 to 7 alone or in combination with one or

more pharmaceutically acceptable, inert, non-toxic excipients or carriers.
Pharmaceutical compositions according to claim 10 comprising at least one active
ingredient according to any one of claims 1 to 7 for use as a partial α
1
- or α
2
-adrenergic
agonist in the treatment of venous disease and migraine.
</CLAIMS>
</TEXT>
</DOC>
